Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH

Robert Cornell; Parameswaran Hari; Shijie Tang; Noa Biran; Natalie Callander; Ajai Chari; Saurabh Chhabra; Mark A. Fiala; Zhubin Gahvari; Ujjawal Gandhi; Kelly Godby; Ridhi Gupta; Sundar Jagannath; Megan Jagosky; Yubin Kang; Ankit Kansagra; Michael Kauffman; Saranya Kodali; Shaji K. Kumar; Arjun Lakshman; Michaela Liedtke; Sagar Lonial; Xiwen Ma; Ehsan Malek; Joshua Mansour; Elizabeth F. McGehee; Amarendra Neppalli; Barry Paul; Paul Richardson; Emma C. Scott; Sharon Shacham; Jatin Shah; David S. Siegel; Elvira Umyarova; Saad Z. Usmani; William Varnado; Ravi Vij; Luciano Costa

doi:10.1002/ajh.26010

Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH

Robert Cornell, Parameswaran Hari, Shijie Tang, Noa Biran, Natalie Callander, Ajai Chari, Saurabh Chhabra, Mark A. Fiala, Zhubin Gahvari, Ujjawal Gandhi, Kelly Godby, Ridhi Gupta, Sundar Jagannath, Megan Jagosky, Yubin Kang, Ankit Kansagra, Michael Kauffman, Saranya Kodali, Shaji K. Kumar, Arjun LakshmanMichaela Liedtke, Sagar Lonial, Xiwen Ma, Ehsan Malek, Joshua Mansour, Elizabeth F. McGehee, Amarendra Neppalli, Barry Paul, Paul Richardson, Emma C. Scott, Sharon Shacham, Jatin Shah, David S. Siegel, Elvira Umyarova, Saad Z. Usmani, William Varnado, Ravi Vij, Luciano Costa

Research output: Contribution to journal › Letter › peer-review

20 Scopus citations

Original language	English
Pages (from-to)	E5-E8
Journal	American journal of hematology
Volume	96
Issue number	1
DOIs	https://doi.org/10.1002/ajh.26010
State	Published - Jan 2021

Access to Document

10.1002/ajh.26010

Cite this

Cornell, R., Hari, P., Tang, S., Biran, N., Callander, N., Chari, A., Chhabra, S., Fiala, M. A., Gahvari, Z., Gandhi, U., Godby, K., Gupta, R., Jagannath, S., Jagosky, M., Kang, Y., Kansagra, A., Kauffman, M., Kodali, S., Kumar, S. K., ... Costa, L. (2021). Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. American journal of hematology, 96(1), E5-E8. https://doi.org/10.1002/ajh.26010

@article{274ae04312104c18b7b439993f04b08a,

title = "Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH",

author = "Robert Cornell and Parameswaran Hari and Shijie Tang and Noa Biran and Natalie Callander and Ajai Chari and Saurabh Chhabra and Fiala, {Mark A.} and Zhubin Gahvari and Ujjawal Gandhi and Kelly Godby and Ridhi Gupta and Sundar Jagannath and Megan Jagosky and Yubin Kang and Ankit Kansagra and Michael Kauffman and Saranya Kodali and Kumar, {Shaji K.} and Arjun Lakshman and Michaela Liedtke and Sagar Lonial and Xiwen Ma and Ehsan Malek and Joshua Mansour and McGehee, {Elizabeth F.} and Amarendra Neppalli and Barry Paul and Paul Richardson and Scott, {Emma C.} and Sharon Shacham and Jatin Shah and Siegel, {David S.} and Elvira Umyarova and Usmani, {Saad Z.} and William Varnado and Ravi Vij and Luciano Costa",

note = "Funding Information: We would like to especially thank all the patients who participated in the studies, and their families. The STORM study (NCT02336815) and the present analysis were funded by Karyopharm Therapeutics, Newton, Massachusetts. The MAMMOTH study was not commercially funded. The authors also acknowledge Liz Anfield, Prime Global, Knutsford, UK, for medical writing support, under the direction of the authors, which was funded by Karyopharm Therapeutics in accordance with Good Publications Practice (GPP3) guidelines. Development of this manuscript was supported by Karyopharm Therapeutics. ",

year = "2021",

month = jan,

doi = "10.1002/ajh.26010",

language = "English",

volume = "96",

pages = "E5--E8",

journal = "American journal of hematology",

issn = "0361-8609",

number = "1",

}

Cornell, R, Hari, P, Tang, S, Biran, N, Callander, N, Chari, A, Chhabra, S, Fiala, MA, Gahvari, Z, Gandhi, U, Godby, K, Gupta, R, Jagannath, S, Jagosky, M, Kang, Y, Kansagra, A, Kauffman, M, Kodali, S, Kumar, SK, Lakshman, A, Liedtke, M, Lonial, S, Ma, X, Malek, E, Mansour, J, McGehee, EF, Neppalli, A, Paul, B, Richardson, P, Scott, EC, Shacham, S, Shah, J, Siegel, DS, Umyarova, E, Usmani, SZ, Varnado, W, Vij, R & Costa, L 2021, 'Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH', American journal of hematology, vol. 96, no. 1, pp. E5-E8. https://doi.org/10.1002/ajh.26010

TY - JOUR

T1 - Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH

AU - Cornell, Robert

AU - Hari, Parameswaran

AU - Tang, Shijie

AU - Biran, Noa

AU - Callander, Natalie

AU - Chari, Ajai

AU - Chhabra, Saurabh

AU - Fiala, Mark A.

AU - Gahvari, Zhubin

AU - Gandhi, Ujjawal

AU - Godby, Kelly

AU - Gupta, Ridhi

AU - Jagannath, Sundar

AU - Jagosky, Megan

AU - Kang, Yubin

AU - Kansagra, Ankit

AU - Kauffman, Michael

AU - Kodali, Saranya

AU - Kumar, Shaji K.

AU - Lakshman, Arjun

AU - Liedtke, Michaela

AU - Lonial, Sagar

AU - Ma, Xiwen

AU - Malek, Ehsan

AU - Mansour, Joshua

AU - McGehee, Elizabeth F.

AU - Neppalli, Amarendra

AU - Paul, Barry

AU - Richardson, Paul

AU - Scott, Emma C.

AU - Shacham, Sharon

AU - Shah, Jatin

AU - Siegel, David S.

AU - Umyarova, Elvira

AU - Usmani, Saad Z.

AU - Varnado, William

AU - Vij, Ravi

AU - Costa, Luciano

N1 - Funding Information: We would like to especially thank all the patients who participated in the studies, and their families. The STORM study (NCT02336815) and the present analysis were funded by Karyopharm Therapeutics, Newton, Massachusetts. The MAMMOTH study was not commercially funded. The authors also acknowledge Liz Anfield, Prime Global, Knutsford, UK, for medical writing support, under the direction of the authors, which was funded by Karyopharm Therapeutics in accordance with Good Publications Practice (GPP3) guidelines. Development of this manuscript was supported by Karyopharm Therapeutics.

PY - 2021/1

Y1 - 2021/1

UR - http://www.scopus.com/inward/record.url?scp=85092920395&partnerID=8YFLogxK

U2 - 10.1002/ajh.26010

DO - 10.1002/ajh.26010

M3 - Letter

C2 - 32974944

AN - SCOPUS:85092920395

SN - 0361-8609

VL - 96

SP - E5-E8

JO - American journal of hematology

JF - American journal of hematology

IS - 1

ER -

Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH

Access to Document

Other files and links

Cite this